In an era of individualized precision medicine, breast cancer is currently clinically staged by the major biomarkers of ER, PR, Ki67 and HER2, with HER2 status being the gold standard for the use of trastuzumab-targeted therapy (60). This evidence concerns the gene MKI67 and breast carcinoma.